Hello researcher, what are you reading? Qun-Ying Yue

Research / 10 April 2020

Right now, i’m working through a couple of interesting things. The first is the book Pharmacovigilance: Critique and Ways Forward, edited by Ralph Edwards and Marie Lindquist – UMC’s former and current director, respectively. This book was first published in 2017, but I’m actually reading the Chinese translation, as that’s my native language and I’m very much involved in training and capacity-building activities in China.

This book is a collection of 18 chapters, written by some of the most experienced pharmacovigilance experts from around the world. It emerged out of a series of meetings of the International Society of Pharmacovigilance to examine the current state of pharmacovigilance, identify its strengths, but also – and in many ways more crucially – draw attention to the shortcomings in the current discipline.

I like that the book takes a broad approach, looking at everything from education, regulation, best practices, research methods, to communications, and quite a lot more. I’m impressed that the authors also put a lot of thought into some of pharmacovigilance’s foundational concepts and they question what the true scope of pharmacovigilance practice should be.

I’m also currently reading several articles on the treatment of the coronavirus infection, COVID-19. In recent years, there has been a lot of effort put into drug repurposing programmes. The potential use of chloroquine on the novel coronavirus SARS-CoV-2 in an urgent situation is an example.

However, we need to be very clear that the current available evidence of the drug’s efficacy and safety for treating COVID-19 is limited and relatively weak. Some treatment guidelines have incorporated the usage of chloroquine and hydroxychloroquine for certain patients with COVID-19, but this will require detailed monitoring and follow-up.

We also need to advise doctors and patients very clearly that chloroquine can lead to serious cardiac problems in some patients – it is known to cause QT interval prolongation – and other side effects, particularly with high dose. In fact, there have been some media reports of serious poisoning cases arising out of self- experimentation. Therefore, people need to be very careful with these drugs and only take them under medical supervision.

Tags: reading

Qun-Ying Yue
Medical Doctor, UMC

You may also like


COVID-19 top priority for research team

Check in with UMC’s head of pharmacovigilance science to catch up with her team’s current research priorities.

Research / 09 April 2021

Pharmacogenomics group aims to refine patient safety options

Better understanding of genetic variation – between individuals and subpopulations – can inform more refined choices of drugs and doses. A new ISoP group is set to drive progress.

Research / 01 July 2020

Causal insights from failure. What pharmacovigilance can teach us about causality

Causality is a tricky business in pharmacovigilance. With limited numbers of adverse event reports, how are we supposed to draw conclusions about causal relationships?

Research / 17 November 2020

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more